Coherus Oncology, Inc.
As of Oct 22, 2026, Coherus Oncology is in Stage 4, the downtrend phase, now in week 17 (since Jun 30, 2026). It closed at $1.05, 58.2% below its 52-week high and below its 200-day average, which is falling.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CHRS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CHRS among Biotechnology319th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …319 | CHRS | Stage 4 · wk 17 | 28 | −16.7% |
Coherus Oncology: quick answers
What stage is Coherus Oncology in?
As of Oct 22, 2026, Coherus Oncology (CHRS) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 30, 2026 and is in week 17. What the four stages mean
Is Coherus Oncology in an uptrend?
No. Coherus Oncology is in a Stage 4 downtrend. It trades 32.2% below its 200-day average, which is falling.
How far is Coherus Oncology from its 52-week high?
Coherus Oncology closed at $1.05 on Oct 22, 2026, 58.2% below its 52-week high of $2.51. Its 52-week low is $0.96.
How has Coherus Oncology performed over the past year?
As of Oct 22, 2026, Coherus Oncology is down 39.7% over the past year and down 23.4% so far in 2026.
Which sector and industry is Coherus Oncology in?
Coherus Oncology is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.